OverviewSuggest Edit

MediWound is a biotechnology company. It is focused on developing, manufacturing and globally commercializing products that address unmet needs in the fields of burn and chronic wound management. MediWound's aim is to provide healthcare professionals and patients with its burn wound eschar removal agent NexoBrid.

TypePublic
Founded2001
HQYavne, IL
Websitemediwound.com

Latest Updates

Employees (est.) (Sept 2020)74
Share Price (Sept 2020)$3.7 (+2%)
Cybersecurity ratingAMore

Key People/Management at MediWound

Sharon Malka

Sharon Malka

Chief Executive Officer
Stephen T. Wills

Stephen T. Wills

Chairman
Vickie R. Driver

Vickie R. Driver

Director
Boaz Gur-Lavie

Boaz Gur-Lavie

Chief Financial Officer
Sharon Kochan

Sharon Kochan

Director
Lior Rosenberg

Lior Rosenberg

Chief Medical Officer
Show more

MediWound Office Locations

MediWound has an office in Yavne
Yavne, IL (HQ)
Ha-Yarkon St 42
Show all (1)

MediWound Financials and Metrics

MediWound Revenue

Market capitalization (25-Sept-2020)

101.0m

Closing stock price (25-Sept-2020)

3.7
MediWound's current market capitalization is $101 m.
Show all financial metrics

MediWound Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

MediWound Online and Social Media Presence

Embed Graph

MediWound News and Updates

MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns

YAVNE, Israel, Sept. 16, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the U.S. Food and Drug Administration (FDA)…

MediWound to Present at Upcoming Investor Conferences in September

YAVNE, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka, MediWound’s Chief Executive Off…

MediWound Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Submitted Biological License Application to the FDA for NexoBrid  EscharEx U.S. Phase 2 Study Resumed Patient Screening

MediWound Reports First Quarter 2020 Financial Results and Provides Corporate Update

EscharEx U.S. Phase 2 Study Resumed Patient Screening EscharEx U.S. Phase 2 Study Resumed Patient Screening

MediWound Provides Corporate Update Related to COVID-19 Pandemic

YAVNE, Israel, March 30, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today provided an update on certain impacts of the COVID-19 pandem…

MediWound Reports Fourth Quarter and Full-Year 2019 Financial Results

Generated total full-year 2019 revenues of $31.8 million, driven primarily by Vericel license payment and development services to BARDA
Show more

MediWound Frequently Asked Questions

  • When was MediWound founded?

    MediWound was founded in 2001.

  • Who are MediWound key executives?

    MediWound's key executives are Sharon Malka, Stephen T. Wills and Vickie R. Driver.

  • How many employees does MediWound have?

    MediWound has 74 employees.

  • Who are MediWound competitors?

    Competitors of MediWound include Urovant Sciences, Cellestia Biotech and Innovation Pharmaceuticals.

  • Where is MediWound headquarters?

    MediWound headquarters is located at Ha-Yarkon St 42, Yavne.

  • Where are MediWound offices?

    MediWound has an office in Yavne.

  • How many offices does MediWound have?

    MediWound has 1 office.